Dec 31, 2016
NCT02874742 : Phase 2 - Daratumumab, Len., Bortezomib & Dex (D-RVd) Vs (RVd) in New MM - GRIFFIN
The GRIFFIN trial Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and...
710
Dec 31, 2016
FDA approves Carfilzomib in combination with Dex or with Lenalidomide and Dex in replased Myeloma
Jan. 21, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the...
124
Dec 30, 2016
NCT02960555: Phase 2 - Isatuximab in Patients With High Risk Smoldering Plasma Cell Myeloma
Isatuximab in Treating Patients With High Risk Smoldering Plasma Cell Myeloma This phase II trial studies how well isatuximab works in...
275
Dec 30, 2016
NCT02659293: Phase 3 - ATLAS Trial: Carfilzomib, Lenalidomide & Dex Vs Lenalidomide Alone After ASCT
NCT02659293: Phase 3: ATLAS Trial: Carfilzomib, Lenalidomide and Dex Vs Lenalidomide Alone After ASCT KRd Vs R NDMM Trial of Carfilzomib,...
349
Dec 24, 2016
NCT01564537: Phase 3 - TOURMALINE-MM1 - Oral Ixazomib + Len/Dex Vs Placebo + Len/Dex RRMM
TOURMALINE-MM1 A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and...
326
Dec 23, 2016
NCT02755597: NCT02755597: Phase 3 - Venetoclax (ABT-199), Bortezomib and Dexamethasone in RRMM
Bellini RRMM A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as...
192
Dec 23, 2016
NCI National Cancer Institute : What Are Clinical Trial Phases?
NCI National Cancer Institute: What Are Clinical Trial Phases? National Cancer Institute Watch to learn about the three main phases of...
128
Dec 22, 2016
NCT02663518: Phase 1: A Trial of TTI-621 for Patients With Hematologic Malignancies and Solid tumors
NCT02663518: Phase 1: A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors NCT02663518: Phase 1: A...
39
Dec 20, 2016
NCT02963493: Phase 2 - Melphalan Flufenamide (Melflufen) With Dexamethasone in Relapsed MM (HORIZON)
HORIZON A Study of Melphalan Flufenamide (Melflufen) in Combination With Dexamethasone in Relapsed Refractory Multiple Myeloma Patients...
209
Dec 17, 2016
NCT02671448: Pilot Trial of Homebound Stem Cell Transplantation
NCT02671448: Pilot Trial of Homebound Stem Cell Transplantation NCT02671448: Pilot Trial of Homebound Stem Cell Transplantation In this...
63
Dec 16, 2016
15th International Myeloma Workshop: September 23-26, 2015, Rome Italy
15th International Myeloma Workshop September, 23-26, 2015, Rome, Italy https://www.myelomasociety.org/publications/ 15th IMW Abstract...
136
Dec 16, 2016
NCT02773030: Phase 1/2: CC-220 Monotherapy and in Combination With Treatments in NDMM / RRMM
CC-220-MM-001 NDMM Newly Diagnosed Multiple Myeloma RRMM Relapsed Refractory Multiple Myeloma A Study to Determine Dose, Safety,...
448
Dec 16, 2016
NCT02863991: Phase 1/2: Oral ONC201 in Relapsed/Refractory Multiple Myeloma
NCT02863991: Phase 1/2: Oral ONC201 in Relapsed/Refractory Multiple Myeloma ONC201 is an orally bioavailable first-in-class small...
57
Dec 16, 2016
NCT02899052: Phase 2: Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in RRMM
NCT02899052: Phase 2: Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory...
97
Dec 16, 2016
NCT02765854: Phase 2: Ixazomib and Dex Vs Ixazomib, Dex and Lenalidomide, With NFKB2 Rearrangement
Multiple Myeloma Research Consortium NCT02765854: Phase 2: Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide,...
59
Dec 15, 2016
NCT02649790: Phase 1/2: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Cancer
RRMM Relapsed Refractory Multiple Myeloma NCT02649790: Phase 1/2: Study of the Safety, Tolerability and Efficacy of KPT-8602 in...
83
Dec 15, 2016
NCT02951819: Phase 2 - Evaluate Dara-CyBorD in Previously Untreated and RRMM - LYRA
A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma NCT02951819: Phase 2 - Evaluate...
88
Dec 15, 2016
Cancer Research Institute: Immunotherapy & Chemotherapy: What's the Difference?
Cancer Research Institute: Immunotherapy & Chemotherapy: What's the Difference? Learn more: https://www.cancerresearch.org
125
Dec 15, 2016
NCT02890758: Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
NCT02890758: Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 Phase I Trial of Universal Donor NK Cell Therapy...
50